Alpex Aims To Block Zydus' Generic Obesity Drug

Law360, New York (July 02, 2013, 10:42 PM ET) -- Swiss drugmaker Alpex Pharma SA on Tuesday hit generic-drug maker Zydus Pharmaceuticals USA Inc. with a patent infringement suit in New Jersey federal court over its bid to market generic versions of Alpex's obesity drug Suprenza. 

In its complaint, Alpex challenged an abbreviated new drug application that Zydus filed with the U.S. Food and Drug Administration, to market 15-mg and 30-mg doses of orally disintegrating phentermine tablets. Zydus is the U.S. subsidiary of India-based Cadila Healthcare Ltd., known as Zydus Cadila, according to the complaint....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required